Bladder Cancer Treatment Market Size and Growth Rate:

“The Bladder Cancer Treatment Market expected to grow at significant CAGR to reach US$ 1,260.8 Mn by 2025. The global bladder cancer treatment market has lucrative opportunities over the seven years forecast period 2019-2025 owing to grow in prevalence of bladder cancer around the globe.”

Bladder Cancer Treatment Market Growth Drivers and Restraints:

For instance, according to World Cancer Research Fund 2018, approximately 550,000 new cases diagnosed with bladder cancer. Moreover, rise in R&D for the development of newer therapeutics for bladder cancer treatment, government initiations to rise in awareness about the cancer diseases among the population, development of advanced therapies, and favorable reimbursement guidelines are expected to propel the global bladder cancer treatment market over the forecast years. However, high cost and adverse effects associated with treatment procedures, delay in disease diagnosis due to asymptomatic nature, and entry of generics into market, are anticipated to hamper the global bladder cancer treatment market.

Browse More Insights of the report @ https://www.precisionbusinessinsights.com/market-reports/global-bladder-cancer-treatment-market/

Immunotherapy Dominates the Global Bladder Cancer Treatment Market

Based on drug class, global bladder cancer treatment market segmented into chemotherapy and immunotherapy. Immunotherapy expected to dominate the global bladder cancer treatment market in 2025 owing to innovation of newer therapeutics by the market players. For instance, in May 2016, Roche received FDA approval for Tecentriq (Atezolizumab), an immunotherapy drug used in the treatment of urothelial carcinoma, a most common type of bladder cancer. Moreover, raise in funding from public and private sectors for R&D activities, patent filings by the market players, and increase in healthcare expenditure are surge the market over the forecast years. However, chemotherapy drugs also have lucrative opportunities over the forecast years due to patent expiration of block buster drugs and launch of generics into market.
North America Dominates the Global Bladder Cancer Treatment Market

PBI’s global bladder cancer treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global bladder cancer treatment market from 2014-2018 and expected to grow at significant growth rate over 2019-2025 owing to frequent FDA approval for the bladder cancer treatment drugs. For instance, in April 2019, Johnson and Johnson received FDA approval for Balversa, a targeted therapy for bladder cancer for the patients with mutations in FGFR gene. Asia Pacific bladder cancer treatment market expected to grow at prominent growth rate owing to entry of market players emerging countries and increase in medical tourism in the region.

Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players

Global bladder cancer treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In April 2018, Roche launched Tecentriq, a bladder cancer treatment drug in India.

Key player’s profiles in the report are AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Co., F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), and Sanofi (France)

Avail Sample of the report @ https://www.precisionbusinessinsights.com/request-sample?product_id=16161

Detailed Segmentation of Bladder Cancer Treatment Market:

By Cancer Type
o Transitional cell bladder cancer
o Invasive bladder cancer
o Superficial bladder cancer
o Squamous cell bladder cancer
o Other rare types
By Drug Class
o Chemotherapy
o Alkylating agents
o Plant alkaloids
o Taxanes
o Anti-tumour Antibiotics
o Anti-metabolites
o Topoisomerase inhibitors
o Immunotherapy
o Tumor-targeting mAbs
o DC-Based immunotherapy
o Peptide- and DNA-based anticancer vaccines
o Immune stimulatory cytokines
o Immune modulatory mAbs
o Immuno suppressive metabolism Inhibitors
o Pattern recognition receptor Agonists
o Others
By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Others
Geography

o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights